https://www.selleckchem.com/products/rp-6306.html
Increased incretin levels may have contributed to but do not completely account for these benefits. Small clinical studies with DPP4 inhibitors demonstrate reduced carotid intimal thickening, improved endothelial function, and reduced arterial stiffness. To date, this has not been translated to cardiovascular risk reduction for individuals with type 2 diabetes with prior or exaggerated risk of cardiovascular disease. DPP4 may represent a key link between central obesity, insulin resistance, and atherosclerosis. The gaps in knowledge in
Gefällt mir
Kommentar
Teilen
